Player Avatar zzlangerhans (99.85) Submitted: 6/7/2009 4:23:35 PM : Underperform Start Price: $17.94 CYTK Score: +5.34

Recent baby bio optimism and a bone from Amgen have combined to puff Cytokinetics stock to an eight month high. But CK-1827452 hasn't been shown to have any clinical benefit yet as trials so far have only evaluated changes in physiologic parameters. The KSP inhibitor program appears to be in tatters, with the remnants being pushed around on the plate by Glaxo. Amgen's 50M, while insignificant for them, will keep Cytokinetics around for a few more waxes and wanes. I'm betting on the next move being a wane.

Featured Broker Partners